Aquestive Therapeutics, Inc. (AQST) stock
AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.78+0.08 (+2.16%)
Close on Nov 18, 2026Market cap $474.43MP/E –Yield –
Aquestive Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Aquestive Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$45.37M. For fiscal 2025 it was -$52.43M. The highest annual figure on record is $5.82M in fiscal 2017.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$52.43M | – |
| FY2024 | Dec 31, 2024 | -$35.76M | – |
| FY2023 | Dec 31, 2023 | -$6.38M | – |
| FY2022 | Dec 31, 2022 | -$9.82M | – |
| FY2021 | Dec 31, 2021 | -$32.98M | – |
| FY2020 | Dec 31, 2020 | -$45.46M | – |
| FY2019 | Dec 31, 2019 | -$60.21M | – |
| FY2018 | Dec 31, 2018 | -$12.99M | -323.1% |
| FY2017 | Dec 31, 2017 | $5.82M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$9.44M | – |
| Q1 FY2026 | Mar 31, 2026 | -$14.81M | – |
| Q4 FY2025 | Dec 31, 2025 | -$8.47M | – |
| Q3 FY2025 | Sep 30, 2025 | -$12.65M | – |
| Q2 FY2025 | Jun 30, 2025 | -$7.91M | – |
| Q1 FY2025 | Mar 31, 2025 | -$23.40M | – |
| Q4 FY2024 | Dec 31, 2024 | -$6.49M | – |
| Q3 FY2024 | Sep 30, 2024 | -$11.88M | – |
| Q2 FY2024 | Jun 30, 2024 | -$7.01M | – |
| Q1 FY2024 | Mar 31, 2024 | -$10.38M | -217.8% |
| Q4 FY2023 | Dec 31, 2023 | -$4.94M | -158.7% |
| Q3 FY2023 | Sep 30, 2023 | -$2.35M | -183.6% |
| Q2 FY2023 | Jun 30, 2023 | -$7.91M | – |
| Q1 FY2023 | Mar 31, 2023 | $8.82M | – |
| Q4 FY2022 | Dec 31, 2022 | $8.42M | – |
| Q3 FY2022 | Sep 30, 2022 | $2.81M | – |
| Q2 FY2022 | Jun 30, 2022 | -$6.56M | – |
| Q1 FY2022 | Mar 31, 2022 | -$14.48M | – |
| Q4 FY2021 | Dec 31, 2021 | -$8.06M | – |
| Q3 FY2021 | Sep 30, 2021 | -$9.07M | – |
| Q2 FY2021 | Jun 30, 2021 | -$1.76M | – |
| Q1 FY2021 | Mar 31, 2021 | -$14.10M | – |
| Q4 FY2020 | Dec 31, 2020 | -$13.51M | – |
| Q3 FY2020 | Sep 30, 2020 | -$8.31M | – |
| Q2 FY2020 | Jun 30, 2020 | -$10.00M | – |
| Q1 FY2020 | Mar 31, 2020 | -$13.64M | – |
| Q4 FY2019 | Dec 31, 2019 | -$10.58M | – |
| Q3 FY2019 | Sep 30, 2019 | -$14.79M | -1983.9% |
| Q2 FY2019 | Jun 30, 2019 | -$17.17M | – |
| Q1 FY2019 | Mar 31, 2019 | -$17.68M | -213.1% |
| Q4 FY2018 | Dec 31, 2018 | -$2.81M | – |
| Q1 FY2018 | Mar 31, 2018 | $785.00K | – |
| Q4 FY2017 | Dec 31, 2017 | -$7.41M | – |
| Q3 FY2017 | Sep 30, 2017 | $15.63M | – |
See a number that looks wrong?